X 22

Drug Profile

X 22

Alternative Names: X-22

Latest Information Update: 25 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 22nd Century
  • Developer 22nd Century; Queen Mary University of London; University of Auckland
  • Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Smoking withdrawal

Most Recent Events

  • 22 Jun 2017 22nd Century receives guidance from the US FDA on phase III trials for Smoking withdrawal
  • 22 Jun 2017 22nd Century and Heracles Pharmaceuticals plans to initiate phase III trials for Smoking withdrawal in USA in the first half of 2018
  • 08 Sep 2015 No recent reports on development identified - Phase-III for Smoking withdrawal in New Zealand (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top